WINTON GROUP Ltd Has $1.10 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

WINTON GROUP Ltd increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 17.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,909 shares of the biotechnology company’s stock after purchasing an additional 9,573 shares during the quarter. WINTON GROUP Ltd’s holdings in ADMA Biologics were worth $1,096,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its position in ADMA Biologics by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock worth $312,109,000 after purchasing an additional 80,302 shares in the last quarter. State Street Corp grew its stake in shares of ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC raised its holdings in shares of ADMA Biologics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after buying an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new position in shares of ADMA Biologics during the 4th quarter worth approximately $62,300,000. Finally, Lord Abbett & CO. LLC acquired a new stake in ADMA Biologics in the 3rd quarter valued at $61,858,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Price Performance

ADMA opened at $20.26 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a market capitalization of $4.79 billion, a P/E ratio of 72.36 and a beta of 0.60. The company’s 50 day simple moving average is $17.13 and its 200-day simple moving average is $18.14. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.